Cabaletta Bio, Inc. (CABA)
NASDAQ: CABA · Real-Time Price · USD
3.020
+0.070 (2.37%)
Jan 27, 2026, 4:00 PM EST - Market closed
Cabaletta Bio Market Cap
Cabaletta Bio has a market cap or net worth of $291.68 million as of January 27, 2026. Its market cap has increased by 157.23% in one year.
Market Cap
291.68M
Enterprise Value
157.05M
1-Year Change
157.23%
Ranking
Category
Stock Price
$3.02
Market Cap Chart
Since October 25, 2019, Cabaletta Bio's market cap has increased from $235.53M to $291.68M, an increase of 23.84%. That is a compound annual growth rate of 3.47%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 26, 2026 | 283.98M | 34.70% |
| Dec 31, 2025 | 210.82M | 90.01% |
| Dec 31, 2024 | 110.95M | -88.59% |
| Dec 29, 2023 | 972.68M | 260.85% |
| Dec 30, 2022 | 269.55M | 151.03% |
| Dec 31, 2021 | 107.38M | -64.23% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Oct 25, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Aardvark Therapeutics | 326.82M |
| Rezolute | 326.40M |
| X4 Pharmaceuticals | 323.52M |
| Puma Biotechnology | 323.51M |
| Atea Pharmaceuticals | 321.88M |
| Fractyl Health | 320.55M |
| Cellectis | 317.62M |
| Larimar Therapeutics | 315.83M |